BamSEC and AlphaSense Join Forces
Learn More

Albireo Pharma Inc

Formerly NASDAQ: ALBO
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 78 pages Certain Information Identified by “[***]” Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. ​ Purchase and Sale Agreement by and Among Albireo Pharma, Inc. and Albireo Ab and Sagard Healthcare Partners (Delaware) LP Dated as of September 22, 2022 ​
12/34/56
EX-10.1
from 8-K 2 pages Albireo Pharma, Inc. Nonemployee Director Compensation Policy
12/34/56
EX-10.36
from 10-K 24 pages Sublease Agreement
12/34/56
EX-10.35
from 10-K 17 pages This Sublease (“Sublease”) Is Made as of December 6, 2021, by and Between Albireo Pharma, Inc. a Delaware Corporation Having an Address of 10 Post Office Square, Boston, Massachusetts 02109 (“Sublandlord”), and Hi Marley, Inc., a Delaware Corporation Having an Address of 77 Franklin St 9th Floor, Boston, Massachusetts 02110 (“Subtenant”)
12/34/56
EX-10.34.4
from 10-K 5 pages Third Amendment to Lease
12/34/56
EX-10.2
from 10-Q 5 pages Albireo Pharma, Inc. Incentive Compensation Recoupment Policy
12/34/56
EX-10.1
from 10-Q 28 pages Asset Purchase Agreement by and Among Albireo Ab, Albireo Pharma, Inc. and Ares Trading SA August 31, 2021
12/34/56
EX-10.1
from 8-K 16 pages Albireo Pharma, Inc. 2018 Equity Incentive Plan, as Amended
12/34/56
EX-10.1
from 10-Q 2 pages Albireo Pharma, Inc. Nonemployee Director Compensation Policy
12/34/56
EX-10.1
from 8-K 50 pages Albireo Pharma, Inc. Common Stock (Par Value $0.01 Per Share) Sales Agreement
12/34/56
EX-10.3
from 10-Q 10 pages Form of Rsu Agreement
12/34/56
EX-10.2
from 10-Q 14 pages Form of Stock Option Agreement
12/34/56
EX-10.1
from 10-Q 43 pages 2020 Inducement Equity Incentive Plan
12/34/56
EX-10.3
from 8-K 8 pages Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[***]”. Such Identified Information Has Been Excluded From This Exhibit Because It Is (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company if Disclosed. Amendment to Royalty Interest Acquisition Agreement
12/34/56
EX-10.2
from 8-K 19 pages Warrant Agreement to Purchase Shares of the Common Stock of Albireo Pharma, Inc. Dated as of __, 2020
12/34/56
EX-10.1
from 8-K 55 pages Agreement
12/34/56
EX-10.2
from 10-Q 9 pages Second Amendment to Lease
12/34/56
EX-10.1
from 10-Q 3 pages Albireo Pharma, Inc. Nonemployee Director Compensation Policy
12/34/56
EX-10.1
from 10-Q 14 pages Employment Agreement
12/34/56
EX-10.1
from 8-K 18 pages Albireo Pharma, Inc. 2018 Equity Incentive Plan, as Amended
12/34/56